Systemic administration of a TGF-β ligand trap decreases phosphorylated SMAD2 in the lungs of a PAH rat model, suggesting that TGF-β exerts at least some of its remodeling effects through canonical signaling in addition to non-canonical pathways (57). This evidence concerns the gene SMAD2 and pulmonary arterial hypertension.